249 related articles for article (PubMed ID: 34075772)
1. A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina.
Kurtovic-Kozaric A; Islamagic E; Asic A; Mehinovic-Cavcic L; Besic L; Sahinbegovic H; Komic H; Kurtovic S; Burazerovic L
Acta Med Acad; 2021 Apr; 50(1):175-196. PubMed ID: 34075772
[TBL] [Abstract][Full Text] [Related]
2. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
3. Molecular findings in myeloid neoplasms.
Tran TB; Siddon AJ
Int J Lab Hematol; 2023 Aug; 45(4):442-448. PubMed ID: 37345257
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC; Agosto-Peña J
Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
[TBL] [Abstract][Full Text] [Related]
5. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
[TBL] [Abstract][Full Text] [Related]
6. Clonal evolution and hierarchy in myeloid malignancies.
Takahashi K; Tanaka T
Trends Cancer; 2023 Sep; 9(9):707-715. PubMed ID: 37302922
[TBL] [Abstract][Full Text] [Related]
7. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
8. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
9. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D
J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456
[TBL] [Abstract][Full Text] [Related]
10. Germ line predisposition to myeloid malignancies appearing in adulthood.
Crysandt M; Brings K; Beier F; Thiede C; Brümmendorf TH; Jost E
Expert Rev Hematol; 2018 Aug; 11(8):625-636. PubMed ID: 29958021
[TBL] [Abstract][Full Text] [Related]
11. [Precursors of acute leukemia: myelodysplastic syndromes and myeloproliferative neoplasms].
Kreipe HH
Pathologe; 2011 Nov; 32 Suppl 2():271-6. PubMed ID: 22033685
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.
Yin CC; Medeiros LJ; Bueso-Ramos CE
Int J Lab Hematol; 2010 Oct; 32(5):461-76. PubMed ID: 20626469
[TBL] [Abstract][Full Text] [Related]
13. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
Kohlmann A; Bacher U; Schnittger S; Haferlach T
Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
[TBL] [Abstract][Full Text] [Related]
14. Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias).
Hasserjian RP; Kelley TW; Weinberg OK; Morgan EA; Fend F
Am J Clin Pathol; 2019 Aug; 152(3):302-321. PubMed ID: 31263893
[TBL] [Abstract][Full Text] [Related]
15. 7q22 deletion in myeloid malignancies: be attentive to the design of the FISH probe.
Struski S; Luquet I
Ann Biol Clin (Paris); 2019 Apr; 77(2):229-230. PubMed ID: 30907375
[No Abstract] [Full Text] [Related]
16. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
17. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
Ronaghy A; Yang RK; Khoury JD; Kanagal-Shamanna R
Curr Hematol Malig Rep; 2020 Jun; 15(3):194-202. PubMed ID: 32382988
[TBL] [Abstract][Full Text] [Related]
18. MDS overlap disorders and diagnostic boundaries.
Tanaka TN; Bejar R
Blood; 2019 Mar; 133(10):1086-1095. PubMed ID: 30670443
[TBL] [Abstract][Full Text] [Related]
19. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.
Tiu RV; Gondek LP; O'Keefe CL; Elson P; Huh J; Mohamedali A; Kulasekararaj A; Advani AS; Paquette R; List AF; Sekeres MA; McDevitt MA; Mufti GJ; Maciejewski JP
Blood; 2011 Apr; 117(17):4552-60. PubMed ID: 21285439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
